LDS/Medical Tests/The Papanicolaou Test (PAP Smear)

The Papanicolaou Test (PAP Smear)

The Papanicolaou test (Pap test) is a screening test for cervical cancer. Cancer of the cervix was the leading cause of cancer death in women before the Pap test began to be widely used. The decrease in incidence of cervix cancer deaths in women can be directly attributed to the widespread use of the Pap test. The test was introduced to the medical community by the work of Dr. George Papanicolaou in collaboration with Dr. Herbert Traut, and published in 1943.

The Papanicolaou (Pap) Test is a screening tool used primarily to detect pre-cancerous and cancerous lesions of the cervix. Testing should begin at age 21 or when a woman becomes sexually active. The test can be performed annually as part of a woman’s well woman visit. However, under current guidelines, women without a history of abnormal Pap smears or a positive High Risk HPV test may have the test performed every 3 years. Clinicians may perform this test when a patient tests positive for High Risk HPV, has abnormal bleeding (especially in a postmenopausal woman), or has lesions found during the pelvic exam or during colposcopy. In addition to conjunctional testing for HPV and Chlamydia and Neisseria, this test may be used to verify infections due to herpes, trichomonas, actinomyces, candida, or bacterial vaginosis. Additionally, some clinicians request a maturation index be performed to gauge hormone levels in peri- and post-menopausal women who may be on hormone therapy.

  • Testing/screening for precancerous changes in the cervix
  • Diagnostic evaluation of symptoms related to the cervix
  • As an aid in diagnosis of cervical cancer
  • Therapy selection for treatment of disease/disordered relate with abnormal PAP
  • Monitoring therapy of cancer of the cervix and other related disorders
  • Follow up of an abnormal Pap test
  • Screening for sexually transmitted infections

Interpretation is based on descriptive categories from the Bethesda System.

Negative for Intraepithelial Lesion**: Includes reactive changes due to repair, infection, inflammation, IUD, radiation therapy, herpes infection

Atypical Squamous Cells of Undetermined Significance (ASCUS): Nuclear enlargement and increased nuclear to cytoplasmic ratios seen in intermediate cells

Atypical Squamous Cells, Cannot Exclude High Grade Intraepithelial Lesion (ASC-H): includes atypical repair. High nuclear to cytoplasmic ratios in immature metaplastic cells

Low Grade Squamous Intraepithelial Lesion (LSIL): Increased nuclear to cytoplasmic ratios in squamous cells, irregular nuclear membranes, hyperchromatic nuclei seen in intermediate cells. HPV changes include cytoplasmic cavitations. Includes mild squamous dysplasia and HPV changes.

High Grade Squamous Intraepithelial Lesion (HSIL): immature metaplastic cells with high nuclear to cytoplasmic ratios. Hyperchromatic nuclei and irregular nuclear membranes are present. Cells present in sheets or tight clusters. Single atypical cells may be seen. Includes moderate squamous dysplasia, severe squamous dysplasia, and squamous cell carcinoma in situ.

Atypical Glandular Cells (AGC): Loss of polarity and crowding of cells. Nucleoli may be present. Nuclear features may include hyperchromasia, and enlargement. Includes Endocervical cells, endometrial cells, and glandular cells, NOS.

Squamous Cell Carcinoma (SCC): Syncytial to clusters of cells with high nuclear to cytoplasmic ratios, hyperchromatic nuclei, and irregular nuclear membranes. Keratinization of cells may be seen. Small, multiple nucleoli may be present. Many single atypical cells may be seen. A tumor diathesis may be seen in the background. Includes keratinizing squamous cells and non-keratinizing squamous cells.

Adenocarcinoma: Cells will be seen “balled” up. Cells will be enlarged with hyperchromatic nuclei. Nuclear membranes will be irregular. Multiple, large nucleoli may be seen. Cytoplasmic vacuoles may be present. Tumor Diathesis may be seen in background. Includes: Endocervical Adenocarcinoma, Endometrial Adenocarcinoma, Adenocarcinoma, NOS.

Negative for Intraepithelial Lesion

 

Cells are collected using some exfoliative process, i.e. brush, spatula from the cervix (ectocervical and endocervical). These collected cells are then placed onto a glass slide and stained with the Papanicolaou stain. Cells are reviewed under a microscope for atypia. Several automated slide makers and staining are available that increases sensitivity and specificity of the methodology (ThinPrep and SurePath). In addition, automated imaging systems are available that scans these slides and saves the image for review and resulting. Autoimaging increases sensitivity and specificity.

Cells from the cervix are collected using a brush or spatula. There are three different methodologies - conventional, ThinPrep, or SurePath - that a clinician can employ. In all methods, cells are transferred onto a glass slide and stained with the Papanicolaou stain so a cytotechnologist and/or pathologist can evaluate the cells. Cells are collected, placed on a glass slide via the collection device, and fixed with alcohol using the Conventional method. These slides are then transported to a laboratory where they will be stained, coverslipped, and interpreted.

There are two types of liquid-based preps available, ThinPrep and SurePath. Both methodologies have cells transferred into a vial of fixative by either swishing the brush in it or breaking off the brush into the vial. Once the vials reach the laboratory, the cells will be extracted mechanically from the vial and placed on a glass slide, stained, coverslipped, and interpreted.

During evaluation, a cytotechnologist will look at the cells on the slide with a microscope. Laboratories can opt to use automated systems to aid in the interpretation of the slides. If they choose to, the ThinPrep methodology will employ the use of a machine that will pre-screen each slide. This machine will pick out 22 fields that it has determined to have the highest probability of atypical cells based on nuclear staining characteristics. The FocalPoint machine can be used if the Conventional or SurePath methodology is used. The FocalPoint will pre-screen the slides and pick out 10 fields of view that have the highest probability of atypical cells based on a cell’s N:C ratio. Once the slides go through either of these machines, the cytotechnologist will use microscopes that access the data from either of these two machines database to screen the slide. The data will guide the scopes to either 22 or 10 fields of view. If any atypical cells are found in these fields, the cytotechnologist will review the entire slide. If no atypia is found, the 10 or 22 fields will be reviewed and the case will be signed out by the cytotechnologist. Slides with atypical findings will be sent for pathologist review.

HPV high risk, HPV genotyping, P16 by IHC, Colposcopy, Biopsy, E6/E7 mRNA using InCellDx or NASBA, Cervix culture, Chlamydia and Neisseria by Nucleic acid amplification (PCR, TMA, SDA), chromosomal abnormality by FISH.
2-4 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Infect Agent Cancer. 2012 Dec 3; 7(1):35. [PMID: 23198689]
  • Int J Cancer. 2012 Nov 26. [PMID: 23180157].
  • Ann Intern Med. 2012 Jun 19;156(12):880-91. [PMID: 22711081].
  • J Med Virol. 2013 Mar;85(3):472-82. [PMID: 23280876].
  • Diagn Cytopathol. 2003 Jul;29(1):38-41. [PMID: 12827715]
  • MMWR Recomm Rep. 2006; 55 (RR–11): 1–94. [PMID: 16888612]
  • Keebler CM and Somrak TM (eds). 1993. The Manual of Cytotechnology. 7th ed. Chicago: ASCP Press. 79-145 p
  • DeMay RM. 1999. Practical Principles of Cytopathology. 1st ed. Chicago: ASCP Press. 1-25 p